LHPP inhibitors are a class of chemical compounds designed to specifically target and inhibit the activity of LHPP (phospholysine phosphohistidine inorganic pyrophosphate phosphatase), a protein that functions as a histidine phosphatase. LHPP plays an important role in cellular processes by dephosphorylating phosphohistidine residues, which are involved in signaling pathways regulating a wide range of biological functions, including metabolism, ion transport, and cellular signaling. Histidine phosphorylation is less understood compared to serine, threonine, and tyrosine phosphorylation, but it is increasingly recognized as an important post-translational modification that contributes to dynamic signaling networks. LHPP regulates these pathways by removing phosphate groups from histidine residues, thus influencing the activation state of proteins involved in various cellular activities. Inhibitors of LHPP disrupt this dephosphorylation process, leading to changes in protein activity and downstream signaling events.
The design of LHPP inhibitors involves identifying small molecules that can specifically bind to the active site of the LHPP enzyme, blocking its ability to interact with phosphohistidine-containing substrates. These inhibitors are crafted to interfere with the enzyme's catalytic mechanism, effectively preventing it from performing its dephosphorylation role. Structural studies of LHPP have provided insights into the arrangement of its active site and the key residues involved in substrate binding, facilitating the development of highly specific inhibitors. By using LHPP inhibitors, researchers can explore the role of histidine phosphorylation in cellular signaling pathways and investigate how LHPP-mediated dephosphorylation influences protein function and metabolic regulation. These inhibitors serve as valuable tools for understanding the complex regulatory mechanisms involving histidine phosphorylation and for studying how changes in this modification can affect broader cellular processes, including signal transduction and energy metabolism.
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
A-769662 | 844499-71-4 | sc-203790 sc-203790A sc-203790B sc-203790C sc-203790D | 10 mg 50 mg 100 mg 500 mg 1 g | $184.00 $741.00 $1076.00 $3417.00 $5304.00 | 23 | |
A769662 is an AMP-activated protein kinase activator, potentially inhibiting LHPP expression via downstream signaling pathways. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a potent phosphoinositide 3-kinase (PI3K) inhibitor, which may disrupt signaling pathways involved in LHPP expression. | ||||||
SL-327 | 305350-87-2 | sc-200685 sc-200685A | 1 mg 10 mg | $107.00 $332.00 | 7 | |
SB-3CT inhibits matrix metalloproteinase (MMP) activity, potentially impacting pathways associated with LHPP expression. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is a selective MAP kinase kinase (MEK) inhibitor, potentially affecting signaling cascades related to LHPP expression. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a potent PI3K inhibitor, which may interfere with pathways involved in the regulation of LHPP expression. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is a potent and reversible inhibitor of c-Jun N-terminal kinase (JNK), potentially influencing pathways related to LHPP. | ||||||
GDC-0941 | 957054-30-7 | sc-364498 sc-364498A | 5 mg 10 mg | $188.00 $199.00 | 2 | |
GDC-0941 is a potent inhibitor of class I PI3K, potentially disrupting signaling pathways involved in the expression of LHPP. | ||||||
NFκB Activation Inhibitor II, JSH-23 | 749886-87-1 | sc-222061 sc-222061C sc-222061A sc-222061B | 5 mg 10 mg 50 mg 100 mg | $214.00 $257.00 $1775.00 $2003.00 | 34 | |
JSH-23 inhibits NF-κB translocation, potentially affecting pathways associated with the regulation of LHPP expression. | ||||||
PI 3-Kγ Inhibitor | 648450-29-7 | sc-203191 | 5 mg | $76.00 | ||
AS601245 is a selective p38 MAP kinase inhibitor, potentially impacting pathways associated with the expression of LHPP. | ||||||
GSK1904529A | 1089283-49-7 | sc-507398 | 10 mg | $321.00 | ||
GSK1904529A is a potent and selective inhibitor of Akt, which may disrupt signaling pathways involved in the regulation of LHPP. | ||||||